{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T21:34:21Z","timestamp":1794087261663,"version":"4.8.0"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T00:00:00Z","timestamp":1647907200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.jns.2022.120194","type":"journal-article","created":{"date-parts":[[2022,2,19]],"date-time":"2022-02-19T18:06:22Z","timestamp":1645293982000},"page":"120194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Medications used to treat tremors"],"prefix":"10.1016","volume":"435","author":[{"given":"Karen","family":"Frei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel D.","family":"Truong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jns.2022.120194_bb0005","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/mds.27121","article-title":"Consensus statement on the classification of tremors. From the task force on tremor of the International Parkinson and Movement Disorder Society","volume":"33","author":"Bhatia","year":"2018","journal-title":"Mov. Disord."},{"issue":"7","key":"10.1016\/j.jns.2022.120194_bb0010","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1212\/WNL.36.7.1001","article-title":"Disability in essential tremor: effect of treatment","volume":"36","author":"Koller","year":"1986","journal-title":"Neurology."},{"key":"10.1016\/j.jns.2022.120194_bb0015","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4137\/JCNSD.S13570","article-title":"Medical treatment of essential tremor","volume":"6","author":"Rajput","year":"2014","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"10.1016\/j.jns.2022.120194_bb0020","article-title":"Essential tremor: new advances","volume":"3","author":"Sepulveda Solo","year":"2020","journal-title":"Clin. Park. Relat. Disord."},{"key":"10.1016\/j.jns.2022.120194_bb0025","first-page":"251","article-title":"Apomorphine in Parkinson\u2019s disease","volume":"56","author":"Schwab","year":"1951","journal-title":"Trans. Am. Neurol. Assoc."},{"issue":"2","key":"10.1016\/j.jns.2022.120194_bb0030","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/1756285616679123","article-title":"Emerging strategies in the management of essential tremor","volume":"10","author":"Hedera","year":"2017","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"Suppl. 3","key":"10.1016\/j.jns.2022.120194_bb0035","first-page":"2","article-title":"Consensus statement of the Movement Disorder Society on tremor. Ad Hoc scientific committee","volume":"13","author":"Deuschl","year":"1998","journal-title":"Mov. Disord."},{"issue":"19","key":"10.1016\/j.jns.2022.120194_bb0040","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1212\/WNL.0b013e318236f0fd","article-title":"Evidence-based guideline update: treatment of essential tremor: report of the Quality Standards subcommittee of the American Academy of Neurology","volume":"77","author":"Zesiewicz","year":"2011","journal-title":"Neurology."},{"issue":"7","key":"10.1016\/j.jns.2022.120194_bb0045","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/mds.27700","article-title":"MDS evidence-based review of treatments for essential tremor","volume":"34","author":"Ferreira","year":"2019","journal-title":"Mov. Disord."},{"issue":"11","key":"10.1016\/j.jns.2022.120194_bb0050","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1002\/mds.22633","article-title":"Synchronized brain network associated with essential tremor as revealed by magnetoencephalography","volume":"24","author":"Schnitzler","year":"2009","journal-title":"Mov. Disord."},{"issue":"Suppl. 1","key":"10.1016\/j.jns.2022.120194_bb0055","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.seizure.2004.04.016","article-title":"Zonisamide: chemistry, mechanism of action, and pharmacokinetics","volume":"13","author":"Leppik","year":"2004","journal-title":"Seizure."},{"issue":"2","key":"10.1016\/j.jns.2022.120194_bb0060","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/mds.21282","article-title":"A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor","volume":"22","author":"Zesiewicz","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2022.120194_bb0065","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.parkreldis.2018.10.010","article-title":"Perampanel, a new hope for essential tremor: an open label trial","volume":"60","author":"Gironell","year":"2019","journal-title":"Parkinsonism Relat. Disord."},{"issue":"4","key":"10.1016\/j.jns.2022.120194_bb0070","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/mdc3.12927","article-title":"A pilot double-blind randomized trial of perampanel for essential tremor","volume":"7","author":"Handforth","year":"2020","journal-title":"Mov. Disord. Clin. Pract."},{"issue":"1","key":"10.1016\/j.jns.2022.120194_bb0075","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/cns.12467","article-title":"Pramipexole at a low dose induces beneficial effect in the Harmaline-induced model of essential tremor in rats","volume":"22","author":"Kosmowska","year":"2016","journal-title":"CNS Neurosci. Ther."},{"issue":"2","key":"10.1016\/j.jns.2022.120194_bb0080","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/WNF.0b013e31824687bf","article-title":"Pramipexole may be an effective treatment option in essential tremor","volume":"35","author":"Herceg","year":"2012","journal-title":"Clin. Neuropharmacol."},{"issue":"1","key":"10.1016\/j.jns.2022.120194_bb0085","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1212\/01.WNL.0000101722.95137.19","article-title":"Pilot trial of 1-octanol in essential tremor","volume":"62","author":"Bushara","year":"2004","journal-title":"Neurology."},{"issue":"12","key":"10.1016\/j.jns.2022.120194_bb0090","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1212\/WNL.62.12.2320","article-title":"Open-label dose-escalation study of oral 1-octanol in patients with essential tremor","volume":"62","author":"Shill","year":"2004","journal-title":"Neurology."},{"issue":"4","key":"10.1016\/j.jns.2022.120194_bb0095","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s13311-011-0045-1","article-title":"An open-label, single-dose, crossover study of the pharmacokinetics and metabolism of two oral formulations of 1-octanol in patients with essential tremor","volume":"8","author":"Nahab","year":"2011","journal-title":"Neurotherapeutics."},{"issue":"10","key":"10.1016\/j.jns.2022.120194_bb0100","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1212\/WNL.0b013e3182840c4f","article-title":"Octanoic acid in alcohol-responsive essential tremor: a randomized controlled study","volume":"80","author":"Haubenberger","year":"2013","journal-title":"Neurology."},{"issue":"8","key":"10.1016\/j.jns.2022.120194_bb0105","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1002\/lary.27695","article-title":"The effect of octanoic acid on essential voice tremor: a double-blind, placebo-controlled study","volume":"129","author":"Lowell","year":"2019","journal-title":"Laryngoscope."},{"key":"10.1016\/j.jns.2022.120194_bb0110","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s12311-018-0994-6","article-title":"Revisiting the clinical phenomenology of \u201ccerebellar tremor\u201d beyond the intention tremor","volume":"18","author":"Lenka","year":"2019","journal-title":"Cerebellum"},{"key":"10.1016\/j.jns.2022.120194_bb0115","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1001\/archneur.1984.04050150058017","article-title":"Pharmacologic trials in the treatment of cerebellar tremor","volume":"4","author":"Koller","year":"1984","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2022.120194_bb0120","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0278-5846(03)00170-2","article-title":"Effects of topiramate in patients with cerebellar tremor","volume":"27","author":"Sechi","year":"2003","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jns.2022.120194_bb0125","first-page":"282","article-title":"Ondansetron, a 5-HT3 antagonist, improves cerebellar tremor","volume":"62","author":"Rice","year":"1997","journal-title":"JNNP."},{"key":"10.1016\/j.jns.2022.120194_bb0130","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1034\/j.1600-0404.2001.00075.x","article-title":"Failure of ondansetron in treatng cerebellar tremor in MS patients- an open-label pilot study","volume":"104","author":"Gbadmosi","year":"2001","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.jns.2022.120194_bb0135","article-title":"Therapeutic advances in the treatment of Holmes tremor: a systematic review","author":"Wang","year":"2020","journal-title":"Neuromodulation."},{"issue":"2","key":"10.1016\/j.jns.2022.120194_bb0140","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1001\/archneur.1993.00540020018011","article-title":"A clinicopathologic study of 100 cases of Parkinson\u2019s disease","volume":"50","author":"Hughes","year":"1993","journal-title":"Arch. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2022.120194_bb0145","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/brain\/awx376","article-title":"Progression of tremor in early stages of Parkinson\u2019s disease: a clinical and neuroimaging study","volume":"141","author":"Pasquini","year":"2018","journal-title":"Brain."},{"issue":"1","key":"10.1016\/j.jns.2022.120194_bb0150","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/ana.410410111","article-title":"Which clinical sign of Parkinson\u2019s disease best reflects the nigrostriatal lesion?","volume":"41","author":"Vingerhoets","year":"1997","journal-title":"Ann. Neurol."},{"issue":"Suppl. 7","key":"10.1016\/j.jns.2022.120194_bb0155","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1002\/mds.10579","article-title":"Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it?","volume":"18","author":"Pirker","year":"2003","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.jns.2022.120194_bb0160","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/mds.21736","article-title":"Paradoxical aspects of parkinsonian tremor","volume":"23","author":"Fishman","year":"2008","journal-title":"Mov. Disord."},{"issue":"11","key":"10.1016\/j.jns.2022.120194_bb0165","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000010316","article-title":"Dopamine-responsive and dopamine-resistant resting tremor in Parkinson disease","volume":"95","author":"Zach","year":"2020","journal-title":"Neurology."},{"issue":"1","key":"10.1016\/j.jns.2022.120194_bb0170","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a008862","article-title":"The history of Parkinson\u2019s disease: early clinical descriptions and neurological therapies","volume":"1","author":"Goetz","year":"2011","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"2","key":"10.1016\/j.jns.2022.120194_bb0175","article-title":"Anticholinergics for symptomatic management of Parkinson\u2019s disease","author":"Katzenschlager","year":"2003","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"10.1016\/j.jns.2022.120194_bb0180","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1001\/archneur.1986.00520020020009","article-title":"Pharmacologic treatment of parkinsonian tremor","volume":"43","author":"Koller","year":"1986","journal-title":"Arch. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2022.120194_bb0185","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/1531-8257(199903)14:2<252::AID-MDS1009>3.0.CO;2-N","article-title":"Reduction of Parkinsonian signs in patients with Parkinson\u2019s disease by dopaminergic versus anticholinergic single-dose challenges","volume":"14","author":"Schrag","year":"1999","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.jns.2022.120194_bb0190","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.biopha.2007.09.002","article-title":"Effect of subcutaneous apomorphine on tremor in idiopathic Parkinson\u2019s disease","volume":"62","author":"Hellmann","year":"2008","journal-title":"Biomed. Pharmacother."},{"issue":"4 Suppl 1","key":"10.1016\/j.jns.2022.120194_bb0195","first-page":"S57","article-title":"Tremor and dopamine agonists","volume":"58","author":"Elble","year":"2002","journal-title":"Neurology."},{"issue":"1","key":"10.1016\/j.jns.2022.120194_bb0200","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/mdc3.12856","article-title":"Treatment responsiveness of motor features in Parkinson\u2019s disease: a matched case-control analysis","volume":"7","author":"Macleod","year":"2020","journal-title":"Mov. Disord. Clin. Pract."},{"issue":"5","key":"10.1016\/j.jns.2022.120194_bb0205","first-page":"301","article-title":"Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson\u2019s disease","volume":"22","author":"Kunig","year":"1999","journal-title":"Clin. Neuropharmacol."},{"issue":"6","key":"10.1016\/j.jns.2022.120194_bb0210","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/jnnp.72.6.713","article-title":"Pramipexole in patients with Parkinson\u2019s disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study","volume":"72","author":"Pogarell","year":"2002","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.jns.2022.120194_bb0215","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/mds.10320","article-title":"Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson\u2019s disease","volume":"18","author":"Navan","year":"2003","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.jns.2022.120194_bb0220","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/00002826-199008000-00005","article-title":"Apomorphine in the diagnosis and treatment of parkinsonian tremor","volume":"13","author":"Hughes","year":"1990","journal-title":"Clin. Neuropharmacol."},{"issue":"12","key":"10.1016\/j.jns.2022.120194_bb0225","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3109\/00207454.2013.812085","article-title":"Rasagiline treatment effects on parkinsonian tremor","volume":"123","author":"Lew","year":"2013","journal-title":"Int. J. Neurosci."},{"issue":"7","key":"10.1016\/j.jns.2022.120194_bb0230","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1001\/jama.1969.03160070046011","article-title":"Amantadine in the treatment of Parkinson\u2019s disease","volume":"208","author":"Schwab","year":"1969","journal-title":"JAMA."},{"issue":"3","key":"10.1016\/j.jns.2022.120194_bb0235","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1600-0404.1986.tb03279.x","article-title":"Clozapine in the treatment of tremor","volume":"73","author":"Pakkenberg","year":"1986","journal-title":"Acta Neurol. Scand."},{"issue":"3","key":"10.1016\/j.jns.2022.120194_bb0240","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/mds.870050307","article-title":"Clozapine-responsive tremor in Parkinson\u2019s disease","volume":"5","author":"Friedman","year":"1990","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.jns.2022.120194_bb0245","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1212\/WNL.48.4.1077","article-title":"Benztropine versus clozapine for the treatment of tremor in Parkinson\u2019s disease","volume":"48","author":"Friedman","year":"1997","journal-title":"Neurology."},{"issue":"6","key":"10.1016\/j.jns.2022.120194_bb0250","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1212\/WNL.49.6.1587","article-title":"Clozapine in Parkinson\u2019s disease tremor. Effects of acute and chronic administration","volume":"49","author":"Bonuccelli","year":"1997","journal-title":"Neurology."},{"issue":"3","key":"10.1016\/j.jns.2022.120194_bb0255","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/mds.870130302","article-title":"Clozapine use in Parkinson\u2019s disease: a retrospective analysis of a large multicentered clinical experience","volume":"13","author":"Trosch","year":"1998","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.jns.2022.120194_bb0260","article-title":"Beta-blocker therapy for tremor in Parkinson\u2019s disease","author":"Crosby","year":"2003","journal-title":"Cochrane Database Syst. Rev."},{"issue":"5","key":"10.1016\/j.jns.2022.120194_bb0265","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1212\/WNL.53.5.1154-a","article-title":"Mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias","volume":"53","author":"Pact","year":"1999","journal-title":"Neurology."},{"issue":"2","key":"10.1016\/j.jns.2022.120194_bb0270","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1353-8020(02)00011-1","article-title":"Mirtazapine in parkinsonian tremor","volume":"9","author":"Gordon","year":"2002","journal-title":"Parkinsonism Relat. Disord."},{"issue":"1\u20132","key":"10.1016\/j.jns.2022.120194_bb0275","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jns.2006.05.039","article-title":"Budipine in Parkinson\u2019s tremor","volume":"248","author":"Reichmann","year":"2006","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2022.120194_bb0280","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/978-3-7091-6360-3_10","article-title":"Tremorlytic activity of budipine in Parkinson\u2019s disease","volume":"56","author":"Spieker","year":"1999","journal-title":"J. Neural Transm. Suppl."},{"issue":"5","key":"10.1016\/j.jns.2022.120194_bb0285","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1001\/archneur.59.5.803","article-title":"Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen","volume":"59","author":"Przuntek","year":"2002","journal-title":"Arch. Neurol."},{"issue":"4","key":"10.1016\/j.jns.2022.120194_bb0290","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0168-0102(01)00298-X","article-title":"Zonisamide has beneficial effects on Parkinson\u2019s disease patients","volume":"41","author":"Murata","year":"2001","journal-title":"Neurosci. Res."},{"issue":"1","key":"10.1016\/j.jns.2022.120194_bb0295","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1212\/01.wnl.0000250236.75053.16","article-title":"Japan Zonisamide on PDSG. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study","volume":"68","author":"Murata","year":"2007","journal-title":"Neurology."},{"issue":"4","key":"10.1016\/j.jns.2022.120194_bb0300","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1111\/j.1468-1331.2010.03276.x","article-title":"Efficacy of zonisamide in a case of Parkinson\u2019s disease with intractable resting and re-emergent tremor","volume":"18","author":"Iijima","year":"2011","journal-title":"Eur. J. Neurol."},{"issue":"14","key":"10.1016\/j.jns.2022.120194_bb0305","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1002\/mds.21717","article-title":"Zonisamide in patients with essential tremor and Parkinson\u2019s disease","volume":"22","author":"Bermejo","year":"2007","journal-title":"Mov. Disord."},{"issue":"7","key":"10.1016\/j.jns.2022.120194_bb0310","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.parkreldis.2012.04.007","article-title":"Actigraphic study of tremor before and after treatment with zonisamide in patients with Parkinson\u2019s disease","volume":"18","author":"Mochio","year":"2012","journal-title":"Parkinsonism Relat. Disord."},{"issue":"10","key":"10.1016\/j.jns.2022.120194_bb0315","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/mds.26286","article-title":"Zonisamide improves wearing-off in Parkinson\u2019s disease: a randomized, double-blind study","volume":"30","author":"Murata","year":"2015","journal-title":"Mov. Disord."},{"issue":"Pt 11","key":"10.1016\/j.jns.2022.120194_bb0320","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1093\/brain\/aws023","article-title":"Cerebral causes and consequences of parkinsonian resting tremor: a tale of two circuits?","volume":"135","author":"Helmich","year":"2012","journal-title":"Brain."},{"issue":"13","key":"10.1016\/j.jns.2022.120194_bb0325","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000005215","article-title":"The nature of postural tremor in Parkinson disease","volume":"90","author":"Dirkx","year":"2018","journal-title":"Neurology."},{"issue":"11","key":"10.1016\/j.jns.2022.120194_bb0330","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1007\/s00415-018-9052-z","article-title":"Differential effects of propranolol on head and upper limb tremor in patients with essential tremor and dystonia","volume":"265","author":"Paparella","year":"2018","journal-title":"J. Neurol."},{"issue":"9","key":"10.1016\/j.jns.2022.120194_bb0335","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/archneur.1987.00520210023013","article-title":"Adjuvant therapy of parkinsonian tremor","volume":"44","author":"Koller","year":"1987","journal-title":"Arch. Neurol."},{"issue":"7","key":"10.1016\/j.jns.2022.120194_bb0340","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.parkreldis.2014.03.013","article-title":"Orthostatic tremor: a review of 45 cases","volume":"20","author":"Yaltho","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.jns.2022.120194_bb0345","article-title":"Slow orthostatic tremor: review of the current evidence","volume":"9","author":"Hassan","year":"2019","journal-title":"Tremor. Other Hyperkinet. Mov. (N Y)"},{"issue":"5","key":"10.1016\/j.jns.2022.120194_bb0350","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1212\/WNL.0000000000002328","article-title":"Orthostatic tremor: clinical, electrophysiologic, and treatment findings in 184 patients","volume":"86","author":"Hassan","year":"2016","journal-title":"Neurology."},{"issue":"5","key":"10.1016\/j.jns.2022.120194_bb0355","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1136\/jnnp.66.5.681","article-title":"Levodopa may improve orthostatic tremor: case report and trial of treatment","volume":"66","author":"Wills","year":"1999","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"10","key":"10.1016\/j.jns.2022.120194_bb0360","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/archneur.57.10.1519","article-title":"Pramipexole is a possible effective treatment for primary orthostatic tremor (shaky leg syndrome)","volume":"57","author":"Finkel","year":"2000","journal-title":"Arch. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2022.120194_bb0365","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1212\/WNL.51.3.880","article-title":"Gabapentin in orthostatic tremor: results of a double-blind crossover with placebo in four patients","volume":"51","author":"Onofrj","year":"1998","journal-title":"Neurology."},{"issue":"7","key":"10.1016\/j.jns.2022.120194_bb0370","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/mds.20392","article-title":"Gabapentin can improve postural stability and quality of life in primary orthostatic tremor","volume":"20","author":"Rodrigues","year":"2005","journal-title":"Mov. Disord."},{"issue":"7","key":"10.1016\/j.jns.2022.120194_bb0375","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/mds.20830","article-title":"Blinded placebo crossover study of gabapentin in primary orthostatic tremor","volume":"21","author":"Rodrigues","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2022.120194_bb0380","doi-asserted-by":"crossref","first-page":"552","DOI":"10.5334\/tohm.414","article-title":"Complete resolution of symptoms of primary orthostatic tremor with Perampanel","volume":"8","author":"Ruiz-Julian","year":"2018","journal-title":"Tremor Other Hyperkinet. Mov. (N Y)."},{"key":"10.1016\/j.jns.2022.120194_bb0385","article-title":"Successful treatment of primary orthostatic tremor using perampanel","volume":"9","author":"Wadhwa","year":"2019","journal-title":"Tremor. Other Hyperkinet. Mov. (N Y)"},{"key":"10.1016\/j.jns.2022.120194_bb0390","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s42466-020-0050-0","article-title":"Remarkable improvement of primary orthostatic tremor using perampanel","volume":"2","author":"Grobe-Einsler","year":"2020","journal-title":"Neurol. Res. Pract."},{"issue":"4","key":"10.1016\/j.jns.2022.120194_bb0395","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000011049","article-title":"Dystonia and tremor: a cross-sectional study of the dystonia coalition cohort","volume":"96","author":"Shaikh","year":"2021","journal-title":"Neurology."},{"issue":"2","key":"10.1016\/j.jns.2022.120194_bb0400","first-page":"181","article-title":"Clinical evaluation of bidirectional torticollis","volume":"5","author":"Truong","year":"1990","journal-title":"Mov. Disord."},{"issue":"9","key":"10.1016\/j.jns.2022.120194_bb0405","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1007\/s10072-020-04402-9","article-title":"Rest tremor in dystonia: epidemiology, differential diagnosis, and pathophysiology","volume":"41","author":"Gupta","year":"2020","journal-title":"Neurol. Sci."},{"issue":"7","key":"10.1016\/j.jns.2022.120194_bb0410","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1136\/jnnp-2013-305532","article-title":"The treatment of dystonic tremor: a systematic review","volume":"85","author":"Fasano","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2022.120194_bb0415","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.parkreldis.2016.03.024","article-title":"Tremor in dystonia","volume":"29","author":"Pandey","year":"2016","journal-title":"Parkinsonism Relat. Disord."},{"issue":"12","key":"10.1016\/j.jns.2022.120194_bb0420","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S1474-4422(05)70250-7","article-title":"Drug-induced tremors","volume":"4","author":"Morgan","year":"2005","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2022.120194_bb0425","article-title":"Drug-induced tremor","volume":"429","author":"Baizabal-Carvallo","year":"2021","journal-title":"J. Neurol. Sci."},{"issue":"5","key":"10.1016\/j.jns.2022.120194_bb0430","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1212\/WNL.40.5.741","article-title":"Movement disorders in alcoholism: a review","volume":"40","author":"Neiman","year":"1990","journal-title":"Neurology."},{"issue":"11","key":"10.1016\/j.jns.2022.120194_bb0435","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1212\/WNL.35.11.1660","article-title":"Tremor in chronic alcoholism","volume":"35","author":"Koller","year":"1985","journal-title":"Neurology."},{"issue":"2","key":"10.1016\/j.jns.2022.120194_bb0445","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/mds.870080210","article-title":"Cocaine-related movement disorders","volume":"8","author":"Cardoso","year":"1993","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.jns.2022.120194_bb0450","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2174\/1874473711205030243","article-title":"Substances of abuse and movement disorders: complex interactions and comorbidities","volume":"5","author":"Deik","year":"2012","journal-title":"Curr. Drug. Abuse Rev."},{"issue":"5","key":"10.1016\/j.jns.2022.120194_bb0455","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1097\/00004583-199309000-00028","article-title":"Side effects of methylphenidate and desipramine alone and in combination in children","volume":"32","author":"Pataki","year":"1993","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"3","key":"10.1016\/j.jns.2022.120194_bb0460","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/00004714-199706000-00012","article-title":"Selective serotonin reuptake inhibitor-induced serotonin syndrome: review","volume":"17","author":"Lane","year":"1997","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.jns.2022.120194_bb0465","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/mds.20325","article-title":"Movement disorder emergencies","volume":"20","author":"Kipps","year":"2005","journal-title":"Mov. Disord."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X22000569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X22000569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T16:00:19Z","timestamp":1758384019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X22000569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":92,"alternative-id":["S0022510X22000569"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2022.120194","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medications used to treat tremors","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2022.120194","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"120194"}}